Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details)

v3.22.4
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Nov. 30, 2022
Aug. 31, 2022
Nov. 30, 2021
 [1],[2]
Aug. 31, 2021
 [2]
Nov. 30, 2022
Nov. 30, 2021
 [1],[2]
May 31, 2022
Summary Of Significant Accounting Policies [Line Items]              
Net loss $ 26,495 $ 20,991 $ 40,077 $ 45,337 $ 47,486 $ 85,414  
Accumulated deficit $ 809,352       809,352   $ 766,131
Charge to APIC due to warrant modification         4,200    
Debt issuance costs         2,100    
Warrant expirations deemed dividend         500    
Extension of warrant expirations deemed dividend         $ 500    
Bulk Drug Substance              
Summary Of Significant Accounting Policies [Line Items]              
Shelf life         4 years    
[1] See Note 2, Summary of Significant Accounting Policies
[2] See Note 2, Summary of Significant Accounting Policies—Revision and Restatement of Financial Statements.